STOK - Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why | Benzinga
Stoke Therapeutics, Inc. (NASDAQ:STOK) reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell on Monday. Here's a look at the highlights.
The Details: The company reported quarterly losses of 60 cents per share which beat the analyst consensus estimate of 63 cents per share by 4.76%.
Quarterly sales came in at $2.8 million which missed the analyst consensus estimate of $3.25 million by 13.82% and is a 14.32% decrease over sales of $3.27 ...